Tari Ao Whānui

I te tīmatanga o Poutū-te-rangi, i whakaaetia e te National Medical Products Administration te Jaypirca® (pirtobrutinib) hei rongoā mō ngā tūroro pakeke e pāngia ana e te mate pukupuku toto mau tonu (CLL) me te mate pukupuku toto iti (SLL) kua whiwhi i te iti rawa i te kotahi te rongoā pūnaha o mua, tae atu ki te mate tyrosin a Bruton...Pānuihia atu»

Kua puta mai he rongo whakahihiri i te Pokapū Arotake Rongoā (CDE) o te Whakahaere Hua Hauora ā-Motu o Haina: kua whakaaetia te whakamātautau haumanu mō te Werohanga KSD-101, i whakawhanakehia e Hensen Bio. Ko te whakamahinga kua tohua ko "ngā pukupuku toto e pā ana ki te EBV e...Pānuihia atu»

Nō nā tata nei, i whakaaetia e te Whakahaere Hua Hauora ā-Motu o Haina (NMPA) tētahi tohu hou mō Bireociclib, he rongoā auaha Akomanga 1 i whakawhanakehia motuhaketia e Xuanzhu Biopharmaceutical. Ko te tohu hou he whakamahi tahi me tētahi aukati aromatase hei rongoā endocrine tuatahi mō...Pānuihia atu»

I te 28 o Pēpuere, 2026, i whakaaetia e te National Medical Products Administration (NMPA) te hokohoko o te JMKX001899 sulfate hei rongoā mō ngā tūroro pakeke e pangia ana e te mate pukupuku pūkahukahu kore-pūtau iti (NSCLC) kua whakarerekētia ki te KRAS G12C, kua whiwhi i te iti rawa i te kotahi te rongoā pūnaha o mua. JMKX00189...Pānuihia atu»

I te 13 o Pēpuere, 2026, i panuitia e te Center for Drug Assessment (CDE) o te National Medical Products Administration o Haina kua whakaurua ngā papa GFH375 ki te Breakthrough Therapy Designation mō te maimoatanga o ngā tūroro e pangia ana e te mate pukupuku pūkahukahu kore-pūtau iti KRAS G12D-mutant (NSCLC) e ...Pānuihia atu»

I te 12 o Pēpuere, 2026, i panuitia e te Center for Drug Assessment (CDE) o te National Medical Products Administration o Haina i te 4 o Pēpuere kua whakaarohia te whakauru i te ENHERTU® (trastuzumab deruxtecan) ki roto i te Breakthrough Therapy Program hei whakamahi hei rongoā tāpiri mō ngā tūroro pakeke me te HER2...Pānuihia atu»

E whakahīhī ana te Tari Ao o te Hōhipera Oncology Rohe Tonga o Beijing ki te tuku i ngā maimoatanga mate pukupuku hou ki ngā tūroro o te ao, tae atu ki te Boron Neutron Capture Therapy (BNCT) – he maimoatanga hou kua huri kē i ngā oranga. He Taunakitanga Tuturu: Te Haerenga a Mrs. Wu i te Tau 2022...Pānuihia atu»

I te 9 o Pēpuere, 2026, i panuitia e te paetukutuku mana o te Center for Drug Evaluation (CDE) o te National Medical Products Administration (NMPA) kua whakamaheretia kia whakawhiwhia ki te Breakthrough Therapy Designation te ZL-1310 mō te werohanga, he hononga hou mō te antibody-drug (ADC) e arotahi ana ki te DLL3. Hei mema...Pānuihia atu»

Mō ia tūroro e haere tawhiti ana ki te rapu i tā mātou tiaki, e tino mārama ana mātou: ko tā koutou e kawe mai nei ehara i te mea ko ngā tuhinga hauora uaua anake engari ko te whakawhirinaki me ngā tumanako o tō whānau katoa. I te Tari Ao o te Hōhipera Oncology Rohe Tonga o Beijing, ka kite mātou i aua kōrero i ia rā—ho...Pānuihia atu»

I te aroaro o te wero maimoatanga o te mate pukupuku koroni HER2-pai, e tino mārama ana mātou ki tō hiahia nui mō ngā kōwhiringa maimoatanga whai hua ake, matatau ake hoki. I tēnei rā, ka kawea mai e mātou ngā purongo whakatenatena nui mai i te mara oncology o Haina. **Kei te tata te Whakaora Pakari: E whakaatu ana a SHR-A1811 i te Motuhake...Pānuihia atu»

Nō nā tata nei, i whakaaetia mana e te Whakahaere Hua Hauora ā-Motu o Haina te whakakotahitanga o te Anlotinib Hydrochloride me te Penpulimab e Chia Tai Tianqing hei rongoā tuatahi mō te mate pukupuku ate kua pāngia. Koinei te tekau o ngā tohu kua whakaaetia mō te Anlotinib Hyd...Pānuihia atu»

Nō nā tata nei, kua eke te mara o te rongoā mate pukupuku i Haina ki tētahi taumata nui. I te 7 o Hānuere, 2025, i whakaaetia e te Whakahaere Hua Hauora ā-Motu te rongoā auaha SHR-1701 mō te whakamahinga mākete. E tohuhia ana me te chemotherapy hei rongoā tuatahi mō te l...Pānuihia atu»